EUCTR2021-005013-14-IT进行中（未招募）1 期
A Phase I/II Combination Study of NMS-03592088 And Azacitidine for the Treatment of Patients With FLT3-Mutated AML with Relapsed /Refractory Disease or Who Are Unfit For Intensive Chemotherapy, or of CMML Patients. - Ph I/II Study of NMS-03592088+Aza in R/R or unfit FLT3-mut AML or CMML Pts
ERVIANO MEDICAL SCIENCES SR0 个研究点目标入组 50 人开始时间: 2021年10月12日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Patients with confirmed diagnosis of de novo or secondary AML as defined by the 2017 ELN recommendations (Dohner H et al., Blood, Jan 2017) positive for FLT3 ITD and/or TKD point mutations in the BM or PB as determined by the local standard test performed at study entry. Patients with an allelic frequency = or > 5 % as determined by local laboratories will be considered to have FLT3-ITD positive disease.
- •Patients must be refractory to at least 1 cycle of induction chemotherapy or relapsed after achieving remission with a prior intensive treatment which may include HSCT. Patients must have received = or < 3 prior therapeutic regimens. Treatments given only for cytoreductive purposes (e.g. hydroxyurea) do not count as prior therapeutic regimen. Patients who received the combination of AZA and a FLT3 inhibitor as last regimen prior to study entry are excluded.
- •Patients deemed unfit for intensive induction chemotherapy or unsuitable or unwilling to receive standard therapy due to age, comorbidities or other factors. Patients must have received no more than 1 prior therapeutic regimen and the regimen should not include the combination of AZA and a FLT3 inhibitor. Treatments given only for cytoreductive purposes (e.g. hydroxyurea) do not count as prior therapeutic regimen.
- •2.Patients with confirmed diagnosis of CMML, as defined by WHO criteria. Patients who have received prior AZA are eligible if the treating physician feels that participation to the study is in the best patients' interest.
- •3. Adult (age = or > 18 years) patients.
- •4.ECOG performance status < or = 2.
- •5.In the absence of rapidly progressing disease, the interval from prior antitumor treatment to time of study drugs administration should be at least 2 weeks for any agents other than hydroxyurea.
- •6.All acute toxic effects (excluding alopecia) of any prior therapy must have resolved to NCI CTCAE version 5.0 Grade < or = 1, unless there is evidence of rapidly progressive disease.
- •7.Adequate hepatic function, as defined by serum transaminases (i.e., AST/ALT) < or = 2.5 x ULN, ALP < or = 2.5 x ULN and total bilirubin < or = 1.5 x ULN unless abnormality considered due to Gilbert’s syndrome.
- •8.Adequate renal function, as defined by the estimated glomerular filtration rate (eGFR) = or > 60 mL/min as calculated by the BSA-unadjusted Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.
- •9.Patients must use highly effective contraception or abstinence. Female patients of childbearing potential must agree to the use of highly effective contraception or abstinence during the period of therapy and in the following 90 days after discontinuation of study treatment. Male patients must be surgically sterile or must agree to use highly effective contraception or abstinence during the period of therapy and in the following 90 days after discontinuation of study treatment.
- •10.Capability to swallow capsules intact (without chewing, crushing, or opening)
- •11.Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study indications or procedures
- •12.Signed and dated IEC or IRB-approved informed consent form indicating that the patient is aware of the neoplastic nature of his/her disease and has been informed of the procedures to be followed, the investigational nature of the therapy, potential benefits, side effects, discomforts, risks and alternative treatments.
- •Are the trial subjects under 18? no
- •Number of subjects f
排除标准
- •1.Current enrollment in another interventional clinical study
- •2.Diagnosis of acute pro-myelocytic leukemia or BCR-ABL-positive leukemia
- •3.Currently active second malignancy, except for adequately treated basal or squamous cell skin cancer and/or cone biopsied in situ carcinoma of the cervix uteri and/or superficial bladder cancer.
- •4.Patients with known leukemia involvement of CNS.
- •5.Hematopoietic stem cell transplantation (HSCT) within 3 months of treatment start and/or persistent non-hematologic toxicities of Grade = or > 2 related to the transplant
- •6.Active acute or chronic graft versus host disease (GVHD) requiring immunosuppressive treatment
- •7.Patients with QTcF interval = or > 480 milliseconds or with risk factors for torsade de pointes (e.g., uncontrolled heart failure, uncontrolled hypokalemia, history of prolonged QTc interval or family history of long QT syndrome). For patients receiving treatment with concomitant medications known to prolong the QTc interval, replacement with another treatment should be considered. If replacement or discontinuation is not clinically feasible, a careful risk/benefit evaluation should be performed prior to enrollment.
- •8.Pregnancy. All female patients with reproductive potential must have a negative pregnancy test (serum or urine) within the screening period prior to start of study drug.
- •9.Breast-feeding or planning to breast feed during the study or within 3 months after study treatment.
- •10.Known hypersensitivity to any components of the NMS-03592088 drug product or AZA drug product.
- •11.Any of the following in the previous 6 months: myocardial infarction, unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis
- •12.Known active, life threatening or clinically significant uncontrolled systemic infection.
- •13.Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness
- •14.Known active Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV) infection requiring systemic treatment.
- •15.Known active gastrointestinal disease (e.g., Crohn’s disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would impact on drug absorption.
- •16.Known active gastrointestinal ulcer
- •17.Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this study or could compromise protocol objectives in the opinion of the Investigator and/or the Sponsor.
研究者
相似试验
招募中
1 期
A Phase I/II Combination Study of NMS-03305293 and Temozolomide in Adult Patients with Recurrent GlioblastomaRecurrent GlioblastomaMedDRA version: 20.0Level: SOCClassification code: 10029104Term: Neoplasms benign malignant and unspecified (incl cysts and polyps) Class: 2CTIS2023-508318-41-00erviano Medical Sciences S.r.l.75
招募中
2 期
A Phase I/II Combination Study of NMS-03305293 and Temozolomide in Adult Patients with Recurrent GlioblastomaDiffuse Glioma10027655GlioblastomaNL-OMON56287erviano Medical Sciences Srl, Italy16
进行中（未招募）
1 期
A study of experimental drug NMS-03305293 in combination with temozolomide in adult patients with a type of brain tumour called glioblastomaMedDRA version: 20.0Level: PTClassification code 10018336Term: GlioblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)GlioblastomaEUCTR2020-003417-35-NLerviano Medical Sciences S.r.l75
进行中（未招募）
1 期
Study of experimental drug NMS-03305293 in combination with Temozolomide in adult patients with recurrent brain tumor.Recurrent glioblastomaMedDRA version: 20.0Level: PTClassification code 10018336Term: GlioblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-003417-35-ITERVIANO MEDICAL SCIENCES SR125
进行中（未招募）
1 期
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986253 Given in Combination with Nivolumab in Patients with Advanced CancersEUCTR2018-000340-26-GBBristol-Myers Squibb International Corporation800